Skip to main content

Bumetanide Injection

Last Updated: January 23, 2023
Status: Current

Products Affected - Description
    • Bumetanide injection, Athenex, 0.25 mg/mL, 10 mL vial, 10 count, NDC 70860-0406-10
    • Bumetanide injection, Athenex, 0.25 mg/mL, 4 mL vial, 10 count, NDC 70860-0405-04
    • Bumetanide injection, Hikma, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00641-6007-10
    • Bumetanide injection, Hikma, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00641-6008-10
    • Bumetanide injection, Pfizer, 0.25 mg/mL, 10 mL vial, 10 count, NDC 00409-1412-10 - discontinued
    • Bumetanide injection, Pfizer, 0.25 mg/mL, 4 mL vial, 10 count, NDC 00409-1412-04 - discontinued
Reason for the Shortage
    • Athenex launched bumetanide injection in February 2022.
    • Hikma did not provide a reason for the shortage.
    • Pfizer has discontinued bumetanide injection in August 2022.
Available Products
    • There is insufficient supply for usual ordering

Estimated Resupply Dates

    • Athenex has bumetanide 0.25 mg/mL 4 mL and vials on back order and the company estimates a release date of February 2023.
    • Hikma has bumetanide 0.25 mg/mL 4 mL and 10 mL vials on allocation.

Updated

Updated January 23, 2023 by Michelle Wheeler, PharmD, Drug Information Specialist. Created April 23, 2021 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2023, Drug Information Service, University of Utah, Salt Lake City, UT.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.